Multidisciplinair Immuno-Oncologie Symposium 2018

Op dinsdag 18 september 2018 vond het Multidisciplinair Immuno-Oncologie Symposium plaats. De presentaties zijn door MEDtalks geregistreerd en op deze website te vinden.

Escape from nonsense mediated decay associates with anti-tumor immunogenicity
Samra Turajlic, medical oncologist, The Francis Crick Institute, London, UK

Short overview of factors that influence the cancer-immune set point
Rudolf Fehrmann, medisch oncoloog, UMCG

Immumotherapy in first line treatment of NSCLC?
Lorenza Landi, Istituto Toscano Tumori, Italy

Behandeling van immuun therapie gerelateerde bijwerkingen met nadruk op de immuun gerelateerde pneumonitis
Jeroen Hiltermann, longarts, UMCG

Merkel cell carcinoma: what can we do with Immunotherapy?
Axel zur Hausen, patholoog, Maastricht UMC+

T-VEC in stadium IIIb/c-IVM1a melanoom
Viola Franke, arts-onderzoeker afdeling Chirurgisch Oncologie, NKI-AvL, Amsterdam

Melanoma: when to stop immuno therapy?
Bart Neyns, medisch oncoloog, UZ Brussel, België

Management immune related toxicity
Karijn Suijkerbuijk, medisch oncoloog, UMCU

How can we make CAR T cell therapy more effective and safer?
Maria Themeli, assistant professor, Cancer Center Amsterdam

Stop & go prospective trial met immunotherapy
Astrid van der Veldt, medisch oncoloog, ErasmusMC

In situ cancer vaccines: tumor ablation and immunotherapy
Gosse Adema, Dept. Molecular Immunology Radiotherapy & OncoImmunology Laboratory, Radboudumc

Non-invasive imaging-based biomarkers?
Regina Beets-Tan, radiologist, NKI-AvL, Amsterdam